Various autoantibodies reacting with nuclear components may be present in the sera of patients with scleroderma. Antibodies that precipitate a soluble 70 000 dalton nuclear protein called Scl-70,2 identified recently as topoisomerase I,3 and antibodies directed against the centromere region of chromosomes have been reported to characterise respectively diffuse systemic sclerosis4 5 Paris. France. 20% of patients with diffuse PSS4 5 and therefore are of limited diagnostic value using standard techniques. Anticentromere antibodies, however, are present in 44-98% of patients with the CREST syndrome6 8 as opposed to only 6-12% in PSS.5 6 9 These data were obtained in studies using routine techniques such as counterimmunoelectrophoresis or immunodiffusion. In the past decade detection of antinuclear antibodies by immunoblotting was introduced. ") The purpose of our study was to analyse the different antinuclear antibodies in a group of 64 patients with PSS from a single centre, to compare the results obtained with different methods, such as immunodiffusion and immunoblotting, for antinuclear antibody determination, and to define the specificity and sensitivity of these autoantibodies and their correlation with the clinical features.
Patients and methods
The study was performed retrospectively. We Incubation with diluted patient's serum (1/20) was performed for two hours in the following buffer: 0-3% bovine serum albumin, 150 mM NaCl, 10 mM TRIS HCI pH 7-6, 0-1 mM PMSF, 1% Triton-X 100, 0-5% deoxycholic acid, and 0-1% sodium dodecyl sulphate. After extensive washing with this buffer (5 Anticentromere antibodies were found in nine and 8), systemic lupus ervt) (82%) of the 11 patients with CREST and in two of (lanes 10, 11, and 12). (Table 3 ) (X2= 152, p<0-0001).
Anti-Scl-70 antibodies were also found in 6/55 ( 11%) patients with SLE, in 2/26 (8%) patients with MCTD, and in none of 30 healthy blood donors ( Table 4) . As calculated from our data the anti-Scl-70 antibody detected with immunoblotting has a specificity of 93% for PSS.
As judged by the clinical features associated with anti-Scl-70 antibodies or anticentromere antibodies, the duration of the disease was significantly shorter in patients with anti-Scl-70 antibodies than in those without (p<002), the mean age was similar in both groups. The two groups did not differ from each other for any other clinical (Table 5) or biological features such as erythrocyte sedimentation rate, rheumatoid factor, serum immunoglobulin concentrations, anti-tissue antibodies. 
